„Generic medicinal product shall mean a medicinal product which has the same qualitative and quantitative composition in active substances and the same pharmaceutical form as the reference medicinal product, and whose bioequivalence with the reference medicinal product has been demonstrated by appropriate bioavailability studies. The different salts, esters, ethers, isomers, mixtures of isomers, complexes of derivatives of an active substance shall be considered to be the same active substance, unless they differ significantly in properties with regard to safety and/or efficacy....“
Innovative drugs and generics – complementary from customer’s perspective
The environment: A
The environment: B
The environment: C Increasing life expectancy – not least an outcome of modern, high effective drugs – results in severe challenges for healthcare systems. The generation 65+ represents 14% of the population, with a drug consumption of approx. 30-40% EU population will decrease from 376mio (2000) to 364mio (2050) Share of working population (15-64) will decrease by 20% Generation 65+ will increase from 61 Mio to 103 Mio
Leading causes of death, SR 2002
Impact of generic market entries
Development of market shares (value)
Status quo of Generics in Slovakia
Christian Wieser General Manager Sandoz Slovakia Prezident asociácie GenasPhone: +421.2.48200.600 Email: christian.wieser@sandoz.com Web: www.sandoz.sk www.genas.sk
Do'stlaringiz bilan baham: |
